Abstract:Abstract Introduction: Despite tremendous progress in cancer immunotherapy, most patients fail to benefit because of poorly characterized immune resistance mechanisms. Among these, expression of the tryptophan-catabolizing enzyme Indoleamine 2,3-dioxygenase (IDO) has been found in several tumors and associated with local immune suppression, notably by inhibiting T cell functions. However, the exact molecular pathways making T cells sensitive to IDO are still unclear. We propose to exploit the power of whole-genome single-guide RNA (sgRNA) CRISPR screens to uncover novel mechanisms of IDO-mediated T cell dysfunction. Methods: Cas9-expressing transgenic mice were crossed with mice expressing a transgenic T cell receptor (TCR) specifically recognizing a tumor antigen called P1A. Primary Cas9xTCRP1A CD8+ T cells were isolated from these mice and stimulated with P1A-expressing tumor cells. Cells were then transduced with the Teichmann retroviral genome wide CRISPR knockout library. Seven days after the first stimulation, CD8+ T cells were re-stimulated in a control (Tryptophanhigh, kynureninelow) or selective (Tryptophanlow, kynureninehigh) medium, mimicking the function of IDO in vitro. After four days of screening selection, genomic DNA was extracted from remaining living cells and sequencing libraries were prepared. sgRNA representation was then assessed by next-generation sequencing. Results: In vitro CRISPR knockout screening pipeline was successfully set up and validated. This includes: (1.) Successful transduction of the CRISPR knockout library, as well as efficient gene knockout in Cas9xTCRP1A primary CD8+ T cells. (2.) Confirming the strong inhibition of T cell proliferation and survival in the selective medium as compared to the control medium, thereby validating the screening selection strategy. (3.) Optimizing genomic DNA extraction procedure, as well as sequencing library preparation. Finally, the proposed in vitro CRISPR knockout screening was successfully launched, and analysis of potential candidate genes is ongoing. Conclusions and perspectives: Our study proposes to perform genome wide CRISPR knockout screens in T cells exposed to conditions mimicking IDO activity in vitro. Enriched sgRNA at the end of the selection should reveal genes whose inhibition improved T cell survival in Tryptophanlow/kynureninehigh medium. Resulting potential candidate targets will then be validated by knocking them out in T cells and assessing T cell functions under conditions mimicking IDO-mediated immune suppression in vitro. Similar validation of top candidate genes will also be performed in vivo in a model of adoptive cell transfer of target-knockout T cells in mice bearing IDO-expressing tumors. The identified genes/pathways involved in T cell sensitivity to Tryptophan shortage/Kynurenine enrichment should reveal new relevant mechanisms of IDO-mediated immune suppression in the tumor microenvironment. Citation Format: Raphaële Bombart, Jingjing Zhu, Benoit J. Van den Eynde. Uncovering molecular actors of IDO-mediated T cell dysfunction with genome-wide CRISPR/Cas9 knockout screens [abstract]. In: Abstracts: AACR Virtual Special Conference: Tumor Immunology and Immunotherapy; 2021 Oct 5-6. Philadelphia (PA): AACR; Cancer Immunol Res 2022;10(1 Suppl):Abstract nr P025.

The Expression Profile of mRNA and tRNA Genes in Splenocytes and Neutrophils after In Vivo Delivery of Antitumor Short Hairpin RNA of Indoleamine 2,3- Dioxygenase

[Knockdown of Indoleamine 2, 3-Dioxygenase 2 (ido2)gene Inhibits Tumor Growth and Enhances Immune Function in Mice Bearing Melanoma].

Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference.

Off-tumor IDO1 Target Engagements Determine the Cancer-Immune Set Point and Predict the Immunotherapeutic Efficacy

Identification of Tumour Immune Infiltration-Associated Snornas (tiisno) for Predicting Prognosis and Immune Landscape in Patients with Colon Cancer Via a TIIsno Score Model.

mRNA-delivery of IDO1 suppresses T cell-mediated autoimmunity

Abstract P025: Uncovering Molecular Actors of IDO-mediated T Cell Dysfunction with Genome-Wide CRISPR/Cas9 Knockout Screens

Abstract 1563: Prediction of immune-checkpoint blockade response in gastrointestinal cancer patients using a machine learning-based RNA signature

The impact of IDO2 expression in B16-BL6 cells on melanoma formation and growth

High-throughput transcriptome profiling indicates ribosomal RNAs to be associated with resistance to immunotherapy in non-small cell lung cancer (NSCLC)

Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor

Gene Silencing Of Indoleamine 2,3-Dioxygenase Hinders Tumor Growth Through Angiogenesis Inhibition

Immunological and Nonimmunological Effects of Indoleamine 2,3-Dioxygenase on Breast Tumor Growth and Spontaneous Metastasis Formation

Preliminary Investigation of Differential Trna-Derived RNA Fragments Expression Profiling and Biological Role in Radioresistant Cervical Squamous Cell Carcinoma

High indoleamine 2,3-dioxygenase transcript levels predict better outcome after front-line cancer immunotherapy

Therapeutic Silence of Pleiotrophin by Targeted Delivery of Sirna and Its Effect on the Inhibition of Tumor Growth and Metastasis

Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment

A New Cancer Immunotherapy Via Simultaneous Dc-Mobilization And Dc-Targeted Ido Gene Silencing Using An Immune-Stimulatory Nanosystem

Advances in Indoleamine 2, 3-Dioxygenase 1 Inhibitors

Evaluation of a blood miRNA/mRNA signature to follow-up Lu-PRRT therapy for G1/G2 intestinal neuroendocrine tumors

A RNA Signature Predicts Outcomes in Immune Checkpoint Blockade Treated Gastrointestinal Cancer Patients.